UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

	x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010

	o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-34494

AGA MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-4757212
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Nos.)

5050 Nathan Lane North, Plymouth, MN		55442
(Address of principal executive offices)		(Zip Code)

(763) 513-9227

(Telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrants were required to submit and post such files). o Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer o

Non-accelerated filer x		Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

There were 50,273,398 shares of AGA Medical Holdings, Inc. common stock with a par value of $0.01 outstanding as of the close of business on November 5, 2010.

Table of Contents

AGA MEDICAL HOLDINGS, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

For the quarterly period ended September 30, 2010

TABLE OF CONTENTS

		Page

PART I. FINANCIAL INFORMATION

ITEM 1.	Financial Statements	1

	Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009	2
	Consolidated Statements Of Operations for the three-and nine-month periods ended September 30, 2010 and September 30, 2009	3
	Consolidated Statements Of Cash Flows for the nine-month periods ended September 30, 2010 and September 30, 2009	4
	Notes to Unaudited Consolidated Financial Statements	5

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	24

ITEM 4.	Controls and Procedures	24

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 3.	Defaults Upon Senior Securities	27

Item 4.	(Removed and Reserved)	27

Item 5.	Other Information	27

Item 6.	Exhibits	27

Signatures		28

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

AGA MEDICAL HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

	September 30, 2010		December 31, 2009
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	19,338	$	24,470
Accounts receivable, less allowance for doubtful accounts of $809 and $481 and discounts of $225 and $395 at September 30, 2010 and December 31, 2009, respectively	48,888		48,730
Inventory	11,893		12,408
Prepaid expenses	1,806		1,408
Income tax receivable	7,815		2,762
Other tax receivable	—		799
Deferred tax assets, net	7,670		8,339
Total current assets	97,410		98,916
Property and equipment, net	36,581		38,669
Goodwill	84,246		85,381
Intangible assets, net	95,237		111,655
Restricted cash	8,278		3,304
Other assets, net	403		379
Deferred tax assets, net	504		—
Deferred financing costs, net	2,167		2,276

Total assets	$	324,826	$	340,580

See notes to unaudited consolidated financial statements.

Table of Contents

AGA MEDICAL HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

	September 30, 2010			December 31, 2009
	(Unaudited)
Liabilities and stockholders’ equity
Current liabilities:
Reserve for customer returns	$	8,814		$	9,335
Trade accounts payable	8,625			8,643
Accrued royalties	2,292			2,299
Accrued interest	1,137			1,462
Accrued wages	11,789			10,549
Short-term obligations to former distributors, less discount	3,341			7,880
Accrued expenses	4,481			5,391
Income taxes payable	297			2,913
Total current liabilities	40,776			48,472
Long-term debt, less current portion	196,963			196,963
Senior subordinated note payable, less discount of $663 and $1,383 at September 30, 2010 and December 31, 2009, respectively	9,337			13,617
Long-term obligations to former distributors, less discount	4,738			9,382
Long-term litigation settlement, less discount	24,914			—
Deferred gain contingency	2,879			—
Deferred tax liabilities	19,152			32,984
Accrued income taxes	2,915			2,705
Stockholders’ equity:
Common stock, $0.01 par value:
Authorized shares—400,000
Issued and outstanding shares—50,268 at September 30, 2010 and 50,094 at December 31, 2009	503			501
Additional paid-in capital	278,654			273,309
Excess purchase price over predecessor basis	(63,500		)	(63,500		)
Accumulated other comprehensive loss	(3,057		)	(489		)
Accumulated deficit	(189,448		)	(173,364		)
Total stockholders’ equity	$	23,152		$	36,457
Total liabilities and stockholders’ equity	$	324,826		$	340,580

See notes to unaudited consolidated financial statements.

Table of Contents

AGA MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2010			2009			2010			2009

Net sales	$	50,481		$	50,158		$	155,507		$	144,540
Cost of goods sold	6,776			6,599			21,763			23,603
Gross profit	43,705			43,559			133,744			120,937

Operating expenses:
Selling, general and administrative	23,527			25,441			73,370			71,897
Research and development	12,028			8,428			33,648			24,905
Litigation settlement	—			—			31,859			—
Amortization of intangible assets	4,954			5,077			14,925			14,972
Change in purchase consideration	(937		)	(353		)	(1,090		)	(1,051		)
Gain on disposal of assets	1			2			—			(23		)
Total operating expenses	39,573			38,595			152,712			110,700
Operating income (loss)	4,132			4,964			(18,968		)	10,237

Investment loss	—			—			—			(2,352		)
Interest income	17			20			77			80
Interest expense	(2,768		)	(3,994		)	(7,219		)	(12,143		)
Other income (expense), net	(450		)	320			(713		)	1,595
Income (loss) before income taxes	931			1,310			(26,823		)	(2,583		)

Income tax benefit	(571		)	(879		)	(10,739		)	(573		)

Net income (loss)	1,502			2,189			(16,084		)	(2,010		)

Less Series A and B preferred stock and Class A common stock dividends	—			(4,569		)	—			(13,040		)

Net income (loss) applicable to common stockholders	$	1,502		$	(2,380	)	$	(16,084	)	$	(15,050	)

Net income (loss) per common share-basic	$	0.03		$	(0.11	)	$	(0.32	)	$	(0.70	)

Net income (loss) per common share-diluted	$	0.03		$	(0.11	)	$	(0.32	)	$	(0.70	)

Weighted average common shares-basic	50,244			21,483			50,168			21,483
Weighted average common shares-diluted	51,189			21,483			50,168			21,483

See notes to unaudited consolidated financial statements.

Table of Contents

AGA MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Nine Months Ended
	September 30, 2010			September 30, 2009
Operating activities
Net loss	$	(16,084	)	$	(2,010	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,280			18,685
Debt discount accretion and deferred financing cost amortization	2,275			2,079
Provision for litigation settlement	24,359			—
Loss on equity investment	—			2,352
Change in deferred taxes	(13,252		)	(3,136		)
Change in purchase accounting consideration	(1,090		)	(1,051		)
Stock-based compensation	3,923			2,538
Excess tax benefits from stock-based compensation	(136		)	—
Gain on disposal of property and equipment	—			(23		)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	(1,410		)	(17,934		)
Inventory	516			2,108
Prepaid expenses and other assets	296			(1,440		)
Income tax receivable	(4,862		)	(65		)
Reserve for customer returns	(448		)	1,214
Trade accounts payable	57			186
Income tax payable	(2,552		)	1,137
Accrued income taxes	210			(680		)
Accrued expenses	988			2,864
Net cash provided by operating activities	12,070			6,824

Investing activities
Acquisitions	(8,003		)	(36,555		)
Purchases of property and equipment	(2,428		)	(7,511		)
Proceeds from litigation settlement	2,759			—
Increase in restricted cash	(4,974		)	(914		)
Net cash used in investing activities	(12,646		)	(44,980		)

Financing activities
Proceeds from long-term debt	—			15,000
Proceeds from revolving line of credit	5,000			15,080
Payments on revolving line of credit	(5,000		)	—
Payments on long-term debt	(5,000		)	—
Payment of deferred financing fees	(666		)	(1,625		)
Additional expenses related to initial public offering of common stock	(89		)	—
Issuance of common stock under employee stock purchase plan	273			—
Proceeds from exercise of stock options	1,105			84
Excess tax benefits from stock-based compensation	136			—
Purchase of Class B common stock	—			(333		)
Net cash provided by (used in) financing activities	(4,241		)	28,206

Effect of exchange rate changes on cash	(315		)	1,043

Net change in cash and cash equivalents	(5,132		)	(8,907		)
Cash and cash equivalents at beginning of period	24,470			22,867
Cash and cash equivalents at end of period	$	19,338		$	13,960
Supplemental disclosures of cash flow information:
Interest paid	$	5,123		$	7,760
Taxes paid	$	8,755		$	3,033

See notes to unaudited consolidated financial statements.

Table of Contents

AGA MEDICAL HOLDINGS, INC.

NOTES TO UNAUDITED CONSOLIDATED

FINANCIAL STATEMENTS

1. Description of Business

AGA Medical Holdings, Inc., a Delaware corporation (AGA Medical or the Company), is a leading innovator and manufacturer of minimally invasive, transcatheter devices to treat structural heart defects and vascular abnormalities, which the Company markets under the AMPLATZER brand. The Company’s occlusion devices are used to occlude, or close, defects, or holes, and have been shown to be highly effective in defect closure. AGA Medical sells its devices to interventional cardiologists, electrophysiologists, interventional radiologists and vascular surgeons in 112 countries through a combination of direct sales and the use of distributors. The Company is investing in research and development, which includes clinical trials, to develop new products and new indications for existing products where there is a significant unmet medical need and a desire to improve the standard of care for patients. All research and development programs take advantage of AGA Medical’s core competencies in braiding thin wires using a shape memory metal alloy, nitinol, which is commonly used in medical devices. The Company has a portfolio of patents to protect its intellectual property rights.

2. Basis of Presentation

The accompanying unaudited financial statements of AGA Medical have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary to present a fair statement of the Company’s consolidated results of operations, financial position and cash flows. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the financial statements and footnotes. Actual results may differ from those estimates. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission on March 4, 2010.

The Company’s common stock, basic and diluted net income (loss) per common share and basic and diluted weighted average shares give effect for all periods to the 1.00 for 7.15 reverse stock split of the Company’s common stock, which occurred immediately prior to the Company’s October 21, 2009 initial public offering of stock.

Reclassification

The balance sheet and cash flow statement reflect the reclassification of certain prior period amounts to conform to the current period presentation.

Critical Accounting Policies and Estimates

There have been no material changes to the Company’s critical accounting policies and estimates as described in Note 2 to the Company’s consolidated financial statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission on March 4, 2010.

Foreign Currency Transaction Gain and Losses

Sales originating in the United States denominated in a currency other than the U.S. dollar are generally fixed in terms of the amount of foreign currency that will be received or paid. A change in exchange rates between the U.S. dollar and the currency in which a transaction is denominated increases or decreases the expected amount of functional currency cash flows upon settlement of the transaction. That increase or decrease in expected functional currency cash flows is a foreign currency transaction gain or loss and is included in determining net income for the period in which the exchange rate changes. In the first quarter of 2009, the Company initiated a foreign currency hedging program. The objectives of the program are to reduce earnings volatility due to movements in foreign currency markets, limit loss in foreign currency-denominated cash flows, and preserve the operating margins of our foreign subsidiaries. The Company generally uses foreign currency forward contracts to hedge transactions related to projected inter-company sales and inter-company debt on a monthly basis. The Company also may hedge firm commitments. These contracts generally relate to obligations associated with our European operations and are denominated primarily in Euros and sterling. All of the Company’s foreign exchange contracts are recognized on the balance sheet at their fair value. The Company does not enter into foreign exchange contracts for speculative purposes. We recorded losses from foreign currency forward contracts of $2.3 million and $0.5 million for the three and nine months ended September 30, 2010, respectively and we recorded gains from foreign currency forward contracts of

Table of Contents

$0.3 million and $0.2 million for the three and nine months ended September 30, 2009, respectively. These are reflected on the consolidated statement of operations in the other income (expense), net line. Amounts on the balance sheet at September 30, 2010 and December 31, 2009 are immaterial.

3. Recent Accounting Pronouncements

In January 2010, the Financial Accounting Standards Board, or FASB, issued ASU 2010-06 which amends the fair value measurements disclosure requirements to require additional disclosures about transfers into and out of Levels 1 and 2 in the fair value hierarchy and additional disclosures about purchases, sales, issuances and settlements relating to Level 3 fair value measurements. Additionally, it clarifies existing fair value disclosures about the level of disaggregation of inputs and valuation techniques used to measure fair value. We have adopted the new disclosure requirements in ASU 2010-06 for the period ended March 31, 2010. The adoption of this statement did not have a material effect on the Company’s consolidated financial statements.

In June 2009, the FASB issued ASC Topic 860 which defines accounting standards for transfers and servicing of financial assets and extinguishments of liabilities. This standard eliminates the concept of a qualifying special-purpose entity, changes the requirements for derecognizing financial assets, and requires additional disclosures. The standard became effective in the first quarter of 2010. The Company adopted ASC Topic 860 effective January 1, 2010. The adoption of this statement did not have a material effect on the Company’s consolidated financial statements.

In June 2009, the FASB issued ASC Topic 810, which defines accounting standards on variable interest entities to address the elimination of the concept of a qualifying special purpose entity. This standard also replaces the quantitative-based risks and rewards calculation for determining which enterprise has a controlling financial interest in a variable interest entity with an approach focused on identifying which enterprise has the power to direct the activities of a variable interest entity and the obligation to absorb losses of the entity or the right to receive benefits from the entity. Additionally, it provides more timely and useful information about an enterprise’s involvement with a variable interest entity. This standard became effective in the first quarter of 2010. The Company adopted ASC Topic 810 effective January 1, 2010. The adoption of this statement did not have a material effect on the Company’s consolidated financial statements.

4. Recent Acquisitions

Effective January 1, 2009, the Company purchased the distribution rights, inventory and intangible assets from its distributor in France. The Company established a wholly-owned subsidiary in France called Amplatzer Medical France SAS. The $3.5 million aggregate purchase price included (i) a payment on April 1, 2009, which, as of the acquisition date, had a net present value of $1.4 million, (ii) $0.8 million for inventory, and (iii) a contingent payment in January 2010, which, as of the acquisition date, had a net present value of $1.3 million payable if certain revenue goals were achieved during this period. On April 1, 2009, the Company made a payment in the amount of $1.4 million. During the quarter ended March 31, 2010, the Company paid the contingent payment due in January 2010, which had a fair value of $1.5 million, the contingent payable amount as of December 31, 2009.

The acquired intangible assets, all of which are being amortized, have a weighted average useful life of approximately eight years. The intangible assets include a customer list valued at $2.7 million. The fair value of the identifiable intangible assets and inventory were determined by management.

On January 1, 2009, the Company purchased the distribution rights, inventory and intangible assets from its two distributors in Portugal. The Company established a wholly-owned subsidiary in Portugal called Amplatzer Medical Portugal, Unipessoal LDA. The $3.5 million aggregate purchase price included payments of $2.5 million in January 2009, $0.2 million for inventory, and a contingent payment in January 2010, which, as of the acquisition date, had a net present value of $0.8 million payable if certain revenue goals were achieved during this period. During the quarter ended March 31, 2010, the Company paid the contingent payments due in January 2010, which had a fair value of $0.8 million, the contingent payable amounts as of December 31, 2009.

The acquired intangible assets, all of which are being amortized, have a weighted average useful life of approximately eight years. The intangible assets include a customer list valued at $3.3 million. The fair value of the identifiable intangible assets and inventory were determined by management.

On January 1, 2009, the Company purchased the distribution rights, inventory and intangible assets from its distributor in the Netherlands. The $1.0 million aggregate purchase price included payments of $0.4 million in January 2009, $0.3 million for inventory, and a contingent payment in January 2010, which, as of the acquisition date, had a net present value of $0.3 million payable if certain revenue goals were achieved during this period. During the quarter ended March 31, 2010, the Company paid the contingent payment due in January 2010, which had a fair value of $0.3 million, the contingent payable amount as of December 31, 2009.

The acquired intangible assets, all of which are being amortized, have a weighted average useful life of approximately eight years. The intangible assets include a customer list valued at $0.7 million. The fair value of the identifiable intangible assets and inventory were determined by management.

Table of Contents

On January 1, 2009, the Company purchased the structural heart product distribution rights, inventory and intangible assets from its distributor in Canada. The Company established a wholly-owned subsidiary in Canada called AGA Medical Canada Inc. The $2.8 million aggregate purchase price included payments of $1.1 million in January 2009, $0.8 million for inventory, and a contingent payment in January 2010 which, as of the acquisition date, had a net present value of $0.9 million payable if certain revenue goals were achieved during this period. During the quarter ended March 31, 2010, the Company paid the contingent payment due in January 2010, which had a fair value of $0.8 million, the contingent payable amount as of December 31, 2009.

The acquired intangible assets, all of which are being amortized, have a weighted average useful life of approximately eight years. The intangible assets include a customer list valued at $2.0 million. The fair value of the identifiable intangible assets and inventory were determined by management.

On January 8, 2009 (and effective as of January 1, 2009), the Company purchased the distribution rights, inventory, equipment, intangible assets and goodwill from its distributor located in Italy, which under ASC Topic 805 constitutes an acquired business. The Company established a wholly-owned subsidiary in Italy called AGA Medical Italia S.R.L. The aggregate purchase price was $41.0 million.

The excess purchase price over the fair value of underlying assets acquired and liabilities assumed was allocated to goodwill. The goodwill recorded as a result of the acquisition is not deductible for income tax purposes. The goodwill represents the strategic benefit of growing the Company’s business and the expected revenue growth from increased market penetration from future products and customers. The following tables summarize the consideration paid and the estimated fair value of the assets acquired at the date of acquisition.

(in thousands)
Consideration:
Cash payment	$	26,600
Discounted guaranteed and contingent debt obligations	14,400
Total consideration	$	41,000
Purchase Price Allocation:
Inventory	$	1,900
Goodwill	21,606
Other intangible assets	26,398
Total assets acquired	$	49,904
Current liabilities	615
Deferred income taxes, net	8,289
Net assets acquired	$	41,000

In addition, the Company has agreed to pay the former owners up to $6.7 million of contingent payments if certain revenue goals are achieved during the first three years following the date of the agreement. The achievements are defined as follows:

Year 2009—$3.1 million guaranteed payment to be paid in January 2010 and a $2.5 million contingent payment payable in January 2010 if gross revenues of AB Medica-AGA Division S.R.L. exceed 20.0 million Euro.

Year 2010—$3.4 million guaranteed payment to be paid in January 2011 and a $2.2 million contingent payment payable in January 2011 if gross revenues of AB Medica-AGA Division S.R.L. exceed 22.0 million Euro.

Year 2011—$3.7 million guaranteed payment to be paid in January 2012 and a $2.0 million contingent payment payable in January 2012 if gross revenues of AB Medica-AGA Division S.R.L. exceed 24.0 million Euro.

On April 1, 2009, the Company made a $2.0 million contingent payment as a result of certain goals that were achieved.

During the quarter ended March 31, 2010, the Company paid $1.3 million relating to the fiscal year 2009 contingent payment and $3.1 million was paid relating to the January 2010 guaranteed payment.

The acquired intangible assets, all of which are being amortized, have a weighted average useful life of approximately eight years. The intangible assets include a customer list valued at $24.8 million and a noncompete agreement valued at $1.6 million. The fair value of the identifiable intangible assets and inventory were determined by management.

On January 1, 2010, the Company purchased the vascular product distribution rights, inventory and intangible assets from its distributor in Canada. The $0.3 million aggregate purchase price included payments of $0.1 million in January 2010, $0.1 million for

Table of Contents

inventory, and a contingent payment in January 2011 which, as of the acquisition date, had a net present value of $0.1 million payable if certain revenue goals are achieved during this period.

The acquired intangible assets, all of which are being amortized, have a weighted average useful life of approximately eight years. The intangible assets include a customer list valued at $0.2 million. The fair value of the identifiable intangible assets and inventory were determined by management.

See note 13 (“Fair Value Measurements”) for the Company’s evaluation of the fair value of all of the Company’s outstanding contingent payments as of September 30, 2010.

5. Goodwill and Intangible Assets

The following table provides a reconciliation of goodwill (in thousands):

Balance as of December 31, 2009	$	85,381
Currency translation effect	(1,135		)
Balance as of September 30, 2010 (unaudited)	$	84,246

Intangible assets consist of the following:

	Weighted Average	As of September 30, 2010 (unaudited)							As of December 31, 2009
(in thousands)	Useful Life (in Years)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trade name	Indefinite	$	10,650	$	—		$	10,650	$	10,650	$	—		$	10,650
Developed technology	6.0	86,650		(51,258		)	35,392		86,650		(43,817		)	42,833
Customer relationships	4.9	63,153		(22,887		)	40,266		64,694		(17,431		)	47,263
Patent rights	7.5	14,500		(7,250		)	7,250		14,500		(5,800		)	8,700
Licensed patent	2.3	1,000		(915		)	85		1,000		(763		)	237
Noncompete agreement	11.8	2,618		(1,024		)	1,594		2,710		(738		)	1,972
		$	178,571	$	(83,334	)	$	95,237	$	180,204	$	(68,549	)	$	111,655

Intangible assets are amortized using methods that approximate the benefit provided by the utilization of the assets. Total amortization expense of intangible assets was $5.0 million and $14.9 million for the three and nine months ended September 30, 2010, respectively, and $5.1 million and $15.0 million for the three and nine months ended September 30, 2009, respectively.

6. Inventories

Inventory is valued at the lower of cost or market with cost determined using the first-in, first-out method. Inventory consists of the following (in thousands):

	September 30, 2010			December 31, 2009
	(unaudited)
Raw materials	$	5,567		$	7,030
Work-in-process	521			360
Finished goods-warehouses	5,474			5,614
Finished goods-consignment	2,059			1,306
Inventory reserve	(1,728		)	(1,902		)
	$	11,893		$	12,408

The Company makes adjustments to the value of inventory based on estimates of potentially excess and obsolete inventory after considering forecasted demand and forecasted average selling prices.

7. Property, and Equipment, Net

Property and equipment, net consist of the following (in thousands):

Table of Contents

	September 30, 2010			December 31, 2009
	(Unaudited)
Manufacturing equipment	$	6,402		$	5,566
Land	5,103			5,103
Office furniture and equipment	4,777			4,762
Computer hardware and software	14,466			12,891
Building	16,123			16,123
Building improvements	1,957			1,651
Leasehold improvements	3,293			3,951
Land improvements	1,493			1,493
Assets not in service	983			1,490
	54,597			53,030
Accumulated depreciation	(18,016		)	(14,361		)
Property and equipment, net	$	36,581		$	38,669

Total depreciation expense for property and equipment was $1.5 million and $4.4 million for the three and nine months ended September 30, 2010, respectively, and $1.4 million and $3.7 million for the three and nine months ended September 30, 2009, respectively.

8. Debt

At December 31, 2008, there was a borrowing of $9.9 million under the Company’s revolving credit facility, with subsequent borrowings of $5.6 million and $9.5 million on January 2, 2009 and March 20, 2009, respectively. Borrowings under the Company’s revolving credit facility bear interest at the alternate base rate or the Eurodollar rate. In March 2009, Bank of America, N.A. assumed the participation of this credit agreement previously held by Lehman Commercial Paper, Inc. The Company fully repaid on October 26, 2009 the amounts outstanding under the Company’s revolving credit facility with net proceeds from its initial public offering and subsequently had $25.0 million of availability under this facility.

On August 3, 2010, the Company’s revolving credit facility was increased from $25.0 million to $40.0 million, with a new maturity date of January 28, 2013. The maturity date will be January 28, 2012 if the senior subordinated notes due 2012 have not been retired in full by January 28, 2012. No change was made to the guarantors, collateral, the representations and warranties or the covenants. The Company recorded deferred financing fees of approximately $0.7 million that will be recorded to interest expense over the term of the revolving credit facility. At September 30, 2010 and December 31, 2009, there were no borrowings under the Company’s revolving credit facility.

On July 28, 2005, the Company entered into a $50.0 million, 10% senior subordinated note agreement with a stockholder. As part of the agreement, the Company issued 6,524 shares of Series A preferred stock valued at $6.5 million, which shares were converted to 912,447 shares of the Company’s common stock immediately prior to completion of our initial public offering. The discounted issue value of the subordinated note was $43.5 million. The senior subordinated notes were fully repaid on October 26, 2009, with proceeds of the Company’s initial public offering. In conjunction with the repayment of the senior subordinated notes the Company recorded a non-cash charge of $2.7 million as interest expense representing the write-off of the unamortized debt discount that remained upon extinguishment.

On January 5, 2009, the Company entered into a $15.0 million, 10% senior subordinated note agreement with a stockholder. As part of the agreement, the Company issued 1,879 shares of Series B preferred stock valued at $1.9 million to the stockholder, which shares were converted to 95,562 shares of the Company’s common stock immediately prior to completion of our initial public offering. The discounted issue value of the subordinated note is $13.1 million. Interest on the senior subordinated note is payable on a semiannual basis. The senior subordinated note has financial and restrictive covenants similar to the Company’s term loan facility covenants. The subordinated note agreement matures on July 28, 2012. The $1.9 million of value assigned to the Series B preferred stock represents a discount from the face value of the note, which will be accreted to its repayment amount utilizing the effective interest method. The Company made a voluntary prepayment of $5.0 million in September 2010, reducing the outstanding principal balance to $10.0 million. In conjunction with the voluntary prepayment the Company recorded a non-cash charge of $0.4 million representing the related portion of the unamortized debt discount.

The term loan facility, revolving credit facility and subordinated note agreements have financial covenants and include various restrictions with respect to the Company. In addition, there are restrictions on indebtedness, liens, guarantees, redemptions, mergers, acquisitions and sales of assets over certain amounts. In addition, the covenants include maximum interest expense coverage, debt and leverage ratios and restrictive covenants, including limitations on new debt, advances to subsidiaries and employees, capital expenditures and transactions with stockholders and affiliates. The Company was in compliance with all covenants at December 31, 2009 and September 30, 2010.

Table of Contents

9. Commitments and Contingencies

Litigation

In August 2006, the Company filed an initial patent infringement suit against Occlutech GmbH (Occlutech), based in Jena Germany. In June 2010 the Regional Court in Dusseldorf entered judgment awarding AGA Medical 2.1 million Euros as damages resulting from Occlutech’s infringement of AGA Medical’s patent. Occlutech has appealed the judgment. In July 2010, as a condition of Occlutech’s appeal, Occlutech paid the Company the damages awarded in the amount of 2.1 million Euros. The Company did not record a gain in its financial results as the appeal process is not yet complete.

On January 29, 2007, Medtronic, Inc. filed a patent infringement action against the Company in the U.S. District Court for the Northern District of California, alleging that substantially all of the Company’s AMPLATZER occluder and vascular plug devices, which have historically accounted for substantially all of the Company’s net sales, infringe three of Medtronic’s method and apparatus patents on shape memory alloy stents (U.S. Patent Nos. 5,190,546, 6,306,141 and 5,067,957, collectively known as the “Jervis patents”). On March 26, 2010, Medtronic and the Company entered into a Settlement and License Agreement in which the parties agreed to settle all issues in the pending litigation. The Company agreed to pay Medtronic the total amount of $35.0 million according to the following schedule: The first payment of $7.5 million was paid in April 2010; the second payment of $7.5 million will be paid in January 2012; and the third and fourth payments of $10.0 million each will be paid in January 2013 and January 2014. Medtronic also granted the Company a royalty-free, paid-up license to the patents at issue for any and all existing Company products, as well as any future Company products that use nitinol for the entire term of the Jervis patents. On March 30, 2010, an order was entered by the court dismissing the litigation with prejudice. The settlement resulted in a charge for the period ended March 31, 2010 of $31.9 million, representing the discounted value of the $35.0 million settlement amount to be paid out over the four-year period.

On November 30, 2007, the University of Minnesota filed a patent infringement action alleging that the Company’s AMPLATZER occlusion devices infringe their method and apparatus patents on septal devices. One of the two patents expired in 2004. The Company believes that it has significant defenses to the litigation, including unenforceability, invalidity and non-infringement. The Company believes this claim is without merit and will continue to vigorously defend its position. As the outcome is uncertain, the Company did not accrue any costs resulting from the claim at September 30, 2010 or December 31, 2009.

On August 24, 2010, the Company filed a patent infringement action against W. L. Gore (“Gore”) alleging that Gore’s HELEX Septal Occluder infringes the Company’s apparatus patent No. 5,944,738 on certain collapsible medical devices. The Company is seeking damages and a permanent injunction. Gore has counterclaimed for invalidity of the patent at issue.

The Company is subject to other various litigation claims in the normal course of business. Management does not believe that any of these claims will have a material impact on the financial statements.

10. Stock-based compensation

Stock-based compensation expense was $1.3 million and $3.9 million for the three and nine months ended September 30, 2010, respectively, and $0.8 million and $2.5 million for the three and nine months ended September 30, 2009, respectively.

11. Income Taxes

The Company uses an estimated annual effective tax rate to determine its quarterly provision for income taxes. The Company has recorded an income tax benefit of $0.6 million and $10.7 million for the three and nine months ended September 30, 2010, respectively, and income tax benefit of $0.9 million and $0.6 million for the three and nine months ended September 30, 2009, respectively. The income tax benefit was subject to an annual loss limitation during the current quarter.

At September 30, 2010 and 2009, the Company had capital loss carryforwards of $5.6 million and $5.7 million, respectively, which expire at various times beginning in 2010 through 2014. The Company has established a valuation allowance against these capital loss carryforwards, as it does not believe they will be realizable in future years. Additionally, the Company has foreign net operating losses from prior years. The Company has released the related valuation allowances based upon its expectations that the net operating loss carryforwards will be utilized.

The Company records all income tax contingency accruals in accordance with ASC Topic 740. At December 31, 2009 and September 30, 2010, the Company had $1.8 million and $2.1 million of unrecognized tax benefits, respectively, including interest and penalties, that, if recognized would result in a reduction of the Company’s effective tax rate. As of December 31, 2009 and September 30, 2010, the Company had approximately $1.2 million and $1.3 million accrued for interest and penalties, respectively. The Company recognizes interest and penalties related to income tax matters in income tax expense and reports the liability in current or long-term income taxes payable, as appropriate.

The Company’s income tax returns are subject to examination for 2006 and subsequent years. The Company’s federal income tax returns that were under examination were concluded by June 30, 2010 with the resulting expense recorded as a discrete item in the second quarter. State and foreign income tax returns are generally subject to examination for a period of three to four years

Table of Contents

after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period up to one year after formal notification to the states.

12. Earnings Per Common Share

Basic net income or loss per share is calculated in accordance with ASC Topic 260. Basic earnings per share (EPS) is calculated using the weighted-average common shares outstanding in each period under the two-class method. The two-class method requires that the Company include in its basic EPS calculation when dilutive, the effect of the Company’s convertible preferred stock as if that stock were converted into common shares. The convertible preferred shares are not included in the Company’s basic EPS calculation when the effect of inclusion would be anti-dilutive.

Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would result in the reduction of a loss or the increase in income per share. For purposes of this calculation, the Company’s stock options are considered to be potential common shares and are only included in the calculation of diluted EPS when the effect is dilutive. The shares used to calculate basic and diluted EPS represent the weighted-average common shares outstanding. The terms of the Company’s preferred stock, all of which converted to common stock in connection with the Company’s initial public offering, included the right to participate with common stockholders in the dividends and unallocated income. Net losses were not allocated to the preferred stockholders. Therefore, when applicable, basic and diluted EPS are calculated using the two-class method as the Company’s convertible preferred stockholders had the right to participate or share in the undistributed earnings with common stockholders. Diluted net loss per common share was the same as basic net loss per share for the nine months ended September 30, 2010 and the three and nine months ended September 30, 2009, since the effect of any potentially dilutive securities was excluded as they were anti-dilutive due to the net loss attributable to common stockholders.

The effect of the Company’s participating convertible Series A and Series B preferred stock is excluded in basic EPS under the two-class method in accordance with ASC Topic 260, for the three and nine months ended September 30, 2009 because the effect is anti-dilutive as a result of the net loss attributable to common stockholders.

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
(in thousands, except per share amounts)	2010		2009			2010			2009

Numerator:
Net income (loss)	$	1,502	$	2,189		$	(16,084	)	$	(2,010	)
Series A and Series B preferred stock and Class A common stock dividends	—		(4,569		)	—			(13,040		)
Net income (loss) applicable to common stockholders	$	1,502	$	(2,380	)	$	(16,084	)	$	(15,050	)
Denominator:
Weighted average common shares outstanding	50,244		20,560			50,168			20,560
Weighted average effect of the assumed conversion of Class A common stock from the date of issuance	—		923			—			923
Weighted average effect of the assumed conversion of Series A and B preferred stock from the date of issuance	—		—			—			—
Weighted average shares of common stock outstanding, basic	50,244		21,483			50,168			21,483

Common Stock Equivalents:
Stock Options	685		—			—			—
Restricted Stock Units	243		—			—			—
Employee Stock Purchase Plan	17		—			—			—
Weighted average shares of common stock outstanding, diluted	51,189		21,483			50,168			21,483

Net income (loss) per share-basic	$	0.03	$	(0.11	)	$	(0.32	)	$	(0.70	)

Net income (loss) per share-diluted	$	0.03	$	(0.11	)	$	(0.32	)	$	(0.70	)

Shares excluded because effect would be anti-dilutive
Common Stock Equivalents:
Conversion of Series A Preferred	—		17,975			—			17,975
Conversion of Series B Preferred	—		96			—			96
Stock Options	931		1,402			1,432			1,410
Restricted Stock Units	—		—			239			—
Employee Stock Purchase Plan	—		—			17			—

Table of Contents

13. Fair Value Measurements

The fair value of assets and liabilities is determined on the exchange price which would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The determination of fair value is based upon a three-tier fair value hierarchy, which prioritizes the inputs used in fair value measurements. The three-tier hierarchy for inputs used in measuring fair value is as follows:

· Level 1—Unadjusted quoted prices in active markets for identical assets or liability

· Level 2—Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets

· Level 3—Unobservable inputs for the asset or liability for which there is little to no market data which requires the entity to develop its own assumption.

The Company recognizes transfers between tiers of the three-tier hierarchy at the end of the period.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The carrying value of cash, cash equivalents and restricted cash approximates fair value at September 30, 2010 and December 31, 2009. Cash, cash equivalents and restricted cash are classified as Level 1 in the fair value hierarchy.

The Company measures the fair value of contingent consideration at each reporting period using Level 3 inputs. The Company has recorded the acquisition date estimated fair value of the contingent payment milestones as a component of consideration transferred using Level 3 inputs. The acquisition date fair values were measured based on the probability and adjusted present value of amounts expected to be paid. The probability adjusted contingent considerations were discounted at the weighted average cost of capital for each acquisition. See note 4 (“Recent Acquisitions”) and the following paragraphs for specific amounts recorded for each acquisition with remaining amounts due in future periods.

On January 8, 2009 (and effective as of January 1, 2009), the Company purchased the distribution rights, inventory, equipment, intangible assets and goodwill from its distributor located in Italy, which under ASC Topic 805 constitutes an acquired business. The Company has agreed to pay the former owners up to $6.7 million of contingent payments if certain revenue goals are achieved during the first three years following the date of the agreement. The achievements are defined as follows:

On April 1, 2009, the Company made a $2.0 million contingent payment as a result of certain goals that were achieved.

As of December 31, 2009, the balance of the contingent obligation recorded was $4.0 million and the discounted value of the guaranteed payment was $9.8 million. In January 2010, $1.3 million was paid relating to the fiscal year 2009 contingent payment and $3.1 million was paid relating to the January 2010 guaranteed payment. For the three and nine month periods ending September 30, 2010, the Company recorded as a reduction to operating expense approximately $0.9 million and $1.1 million, respectively. As of September 30, 2010, the balance of the contingent obligation recorded was $1.4 million.

Table of Contents

In conjunction with the January 1, 2010 purchase of the vascular distribution rights, inventory and intangible assets from the Company’s distributor in Canada, a contingent payment payable in January 2011, which as of the acquisition date had a net present value of $0.1 million payable if certain revenue goals are achieved during this period, was recorded. As of September 30, 2010, the balance of the contingent obligation recorded was $0.1 million.

The following table represents a summary of the contingent consideration liability and activity (in thousands) for the periods presented:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2010			2009			2010			2009
Contingent Consideration:
Balance at Beginning of Period	$	2,258		$	8,144		$	7,457		$	—
Purchase price contingent consideration	—			—			100			10,558
Payments	—			—			(4,727		)	(2,000		)
Change in fair value of contingent consideration (included in the statement of operations)	(937		)	(353		)	(1,090		)	(1,051		)
Currency translation effect	207			(94		)	(212		)	190
Balance at End of Period	$	1,528		$	7,697		$	1,528		$	7,697

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

During the three and nine month periods ended September 30, 2010 and September 30, 2009 we had no significant fair value measurements of assets or liabilities at fair value subsequent to their initial recognition, except as disclosed in Note 14.

Fair Value of Financial Instruments

The carrying value of the Company’s debt instruments approximates fair value for all periods presented.

14. Equity Method Investment

During the first quarter of 2009, the Company determined that its equity method investment in Ample Medical, Inc. was other-than-temporarily impaired and wrote-off the remaining investment balance to its fair value of $0.0 million. The loss on impairment of $2.3 million is recorded in the investment loss line item on the statement of operations for the nine months ended September 30, 2009.

15. Comprehensive Income

Comprehensive income consists of net income and the effects of foreign currency translation. The following table provides a reconciliation of net income (loss) to comprehensive income (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010			2009

Net income (loss)	$	1,502	$	2,189	$	(16,084	)	$	(2,010	)
Changes in foreign currency translation	5,871		1,654		(2,568		)	2,085
Total comprehensive income (loss)	$	7,373	$	3,843	$	(18,652	)	$	75

16. Segment Information

We review our operations and manage our business as one reportable segment where we develop, manufacture and market our products which are sold in 112 countries through a combination of direct sales and the use of distributors. Factors used to identify our single operating segment include the financial information available for evaluation by our chief operating decision maker in making decisions about how to allocate resources and assess performance.

Net sales to external customers and long-lived assets by geography are as follows (in thousands):

Table of Contents

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010		2009

Net sales:
United States	$	19,920	$	19,268	$	58,500	$	56,018
International:
Europe (exclusive of Italy)	14,594		15,970		46,278		44,723
Italy	4,924		5,483		16,981		16,862
Other	11,043		9,437		33,748		26,937
Total International	30,561		30,890		97,007		88,522

Total net sales	$	50,481	$	50,158	$	155,507	$	144,540

	September 30, 2010		December 31, 2009
	(Unaudited)
Long-lived assets:
United States	$	165,132	$	172,328
Italy	40,517		45,394
International (exclusive of Italy)	21,767		23,942
Total long-lived assets	$	227,416	$	241,664

We are not dependent on any single customer, and no single customer (including distributors) accounted for more than 10% of our net sales for the three and nine months ended September 30, 2010 and 2009.

17. Subsequent Events

On October 15, 2010, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with St. Jude Medical, Inc., a Minnesota company (“St. Jude”), and its indirect wholly owned subsidiary, Asteroid Subsidiary Corporation, a Delaware corporation. Pursuant to the Merger Agreement, on October 20, 2010, Asteroid Subsidiary Corporation commenced an exchange offer to purchase all of our outstanding shares of our common stock at a purchase price of $20.80 per share, payable in cash and/or St. Jude common stock, at the tendering stockholders’ election, subject to proration and adjustment as provided in the Merger Agreement, in order for 50% of the total consideration payable in the exchange offer consist of cash and 50% to consist of St. Jude common stock. The exchange offer will remain open for at least 20 business days and will expire, unless extended or terminated in accordance with its terms, at 12:00 midnight (one minute after 11:59 p.m.), New York City time, on the evening of November 17, 2010. As soon as practicable after the consummation of the exchange offer and satisfaction or waiver of certain conditions set forth in the Merger Agreement, Asteroid Subsidiary Corporation will merge with and into AGA Medical Holdings, Inc., and AGA Medical Holdings, Inc. will become a direct wholly-owned subsidiary of St. Jude Medical, which is expected to be followed by a second merger of AGA Medical Holdings, Inc. into another wholly-owned subsidiary of St. Jude.

The Merger Agreement provides that completion of the exchange offer will be subject to certain conditions, including (i) stockholders holding a majority of our outstanding common shares tendering in the exchange offer, calculated on a fully-diluted basis, (ii) the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and under any non-U.S. antitrust, competition or similar notification or clearance laws, (iii) St. Jude’s registration statement on Form S-4, relating to the St. Jude common stock to be issued in the exchange offer, being declared effective by the Securities and Exchange Commission, and (iv) the absence of a Material Adverse Effect (as defined in the Merger Agreement) since the date of the Merger Agreement. The exchange offer is not conditioned on the ability of St. Jude or Asteroid Subsidiary Corporation to obtain third party financing.

The Merger Agreement also includes customary covenants governing the conduct of our business prior to completion of the merger, including the use of commercially reasonable efforts to operate our business in the ordinary course until the effective time of the merger. We have agreed not to solicit or initiate discussions with third parties regarding other proposals to acquire the Company and to certain restrictions on its ability to respond to any such proposal, subject to fulfillment of certain fiduciary requirements of our board of directors. The Merger Agreement contains termination rights for both the Company and St. Jude upon various customary circumstances, including if the exchange offer is not completed on or before March 1, 2011, and provides, among other things, that if termination of the Merger Agreement relates to us entering into an acquisition agreement with another party, we will be required to pay St. Jude a termination fee. In such instances, if the alternative transaction is with a party who submitted a proposal received by us prior to 11:59 p.m. Central Time on November 2, 2010 and we notified St. Jude prior to 11:59 p.m. Central Time on November 3,

Table of Contents

2010 of our Board’s determination that such proposal was or was reasonably likely to result in a superior proposal to the transaction described in the Merger Agreement, the termination fee will be equal to $21,650,000 (approximately 2% of the equity value for the transaction). In other circumstances when a termination fee is payable under the Merger Agreement, the termination fee payable will be equal to $32,475,000 (approximately 3% of the equity value for the transaction). Under certain circumstances, termination of the Merger Agreement does not preclude St. Jude and Asteroid Subsidiary Corporation from amending and continuing the Offer and promptly disclosing that such Offer is no longer pursuant to the Merger Agreement with AGA.

A copy of the Merger Agreement was attached as Exhibit 2.1 to our Current Report on Form 8-K filed October 18, 2010 and is incorporated herein by reference.

As previously disclosed in Note 17 to our unaudited consolidated financial statements included in Part I, Item 1 of the Form 10-Q for the quarter ended June 30, 2010, in June 2010, the Regional Court in Dusseldorf entered a judgment in our favor relating to our August 2006 patent infringement suit against Occlutech GmbH (“Occlutech”), based in Jena, Germany. The Regional Court in Dusseldorf awarded us 2.1 million Euros as damages. Occlutech has appealed the judgment. In July 2010, as a condition of Occlutech’s appeal, Occlutech paid the Company the damages awarded in the amount of 2.1 million Euros; we did not, however, record a gain in our financial results as the appeal process is not yet complete. Further, in conjunction with this judgment award, we were required to post a $2.5 million letter of credit with the Regional Court in Dusseldorf. In addition, subsequent to the end of our third fiscal quarter, and relating to our appeal of a 2008 non-infringement declaration in favor of Occlutech in the Patent Court in the Netherlands, on October 19, 2010, the Hague Court of Appeal affirmed the lower court’s ruling.

On October 29, 2010, a putative stockholder class action complaint was filed in Hennepin County District Court, Fourth Judicial District Court, State of Minnesota. The complaint, captioned Michael Rubin v. AGA Medical Holdings, Inc., et al., names as defendants the members of the Company’s Board of Directors, as well as the Company, Parent, Purchaser, Welsh, Carson, Anderson & Stowe IX, L.P., WCAS Capital Partners IV, L.P., Gougeon Shares, LLC and The Franck L. Gougeon Revocable Trust. The plaintiff alleges that the Company’s directors breached their fiduciary duties to the Company’s stockholders. The complaint also alleges that the Company’s purported controlling stockholders owed fiduciary duties to the Company’s minority stockholders in connection with the transaction and breached such duties. The plaintiff further claims that Parent and its subsidiaries aided and abetted the purported breaches of fiduciary duty. The complaint alleges, inter alia, that in approving the proposed transaction between the Company and Parent, Company Board members accepted an inadequate price, failed to make full disclosure, and utilized unreasonable deal protection devices and that the Company Board members acted to put their personal interests ahead of the interests of Company stockholders. The complaint seeks injunctive relief, including to enjoin the transaction, in addition to unspecified compensatory damages, attorneys’ fees, other fees and costs and other relief. The Company believes the plaintiff’s allegations lack merit. The foregoing description is qualified in its entirety by reference to the complaint, which is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

On October 28, 2010, a putative stockholder class action complaint was filed in the Delaware Court of Chancery. The complaint, captioned Jennifer Walling v. AGA Medical Holdings, Inc., et al., names as defendants the members of the Company’s Board of Directors, as well as the Company, Parent and Purchaser. The plaintiff alleges that the Company’s directors breached their fiduciary duties to the Company’s stockholders and further alleges that the Company and Parent aided and abetted the purported breaches of fiduciary duty. The complaint alleges, inter alia, that in approving the proposed transaction between the Company and Parent, Company Board members accepted an inadequate price, failed to make full disclosure, and utilized unreasonable deal protection devices and that the Company Board members acted to put their personal interests ahead of the interests of Company stockholders. The complaint seeks injunctive relief, including to enjoin the transaction, in addition to unspecified compensatory damages, attorneys’ fees, other fees and costs and other relief. The Company believes the plaintiff’s allegations lack merit. The foregoing description is qualified in its entirety by reference to the complaint, which is filed as Exhibit 99.2 hereto and is incorporated herein by reference.

Table of Contents

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including, in particular, statements related to the following: (i) pending litigation, (ii) regulatory approval of our products and the results of clinical trials; (iii) our market position; (iv) our anticipated future cash flows, liquidity requirements, and sources of liquidity; (v) our expected merger with St. Jude Medical, Inc.; and (vi) any statements about our plans, strategies and prospects. These statements are based on the beliefs of management as well as assumptions made by, and information currently available to, us. These statements reflect our current views with respect to future events, are not guarantees of future performance and involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These factors include, among other things:

· failure to implement our business strategy;

· failure to capitalize on our expected market opportunities;

· lack of regulatory approval and market acceptance of our new products, product enhancements or new applications for existing products;

· regulatory developments in key markets for our AMPLATZER occlusion devices;

· failure to complete our clinical trials or failure to achieve the desired results in our clinical trials;

· inability to successfully commercialize our existing and future research and development programs;

· failure to protect our intellectual property;

· intellectual property claims exposure, related litigation expense, and any resultant damages, awarded royalties or other remedies, in particular resulting from our Medtronic and Occlutech litigations;

· competition;

· decreased demand for our products;

· product liability claims exposure;

· failure to comply with laws and regulations;

· changes in general economic and business conditions;

· changes in currency exchange rates and interest rates;

· the delay or termination of our expected merger with St. Jude Medical, Inc., and the likelihood of additional costs and diversion of management attention associated with completing the transaction and defending lawsuits related thereto; and

· other risks and uncertainties, disclosed in our filings with the Securities and Exchange Commission, including those detailed in our Annual Report on Form 10-K for the year ended December 31, 2009 filed on March 4, 2010.

You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause our results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, we do not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review our filings with the Securities and Exchange Commission (which are available from the SEC’s EDGAR database at www.sec.gov, at various SEC reference facilities in the United States and via our website at www.amplatzer.com).

Table of Contents

PART I — FINANCIAL INFORMATION

Explanatory note: Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to (1) “we,” “us,” “our” and the “Company” refer collectively to AGA Medical Holdings, Inc. and its consolidated subsidiaries and (2) “AGA Medical” refers to AGA Medical Corporation, a wholly-owned subsidiary of the Company.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a leading innovator and manufacturer of medical devices for the minimally invasive treatment of structural heart defects and vascular abnormalities. Our AMPLATZER occlusion devices offer transcatheter treatments that have been clinically shown to be highly effective in defect closure. Our devices and delivery systems use relatively small catheters and can be retrieved and repositioned prior to release from the delivery cable, enabling optimal placement without the need to repeat the procedure or use multiple devices. We are the only manufacturer with occlusion devices approved to close seven different structural heart defects, and we believe we have the leading market positions in the United States and Europe for each of our devices. We sell our devices to interventional cardiologists, interventional radiologists, vascular surgeons and electrophysiologists in 112 countries through a combination of direct sales and the use of distributors, with international markets representing 60.5% and 62.4% of our net sales for the three and nine months ended September 30, 2010, respectively, and 61.6% and 61.2% of our net sales for the three and nine months ended September 30, 2009, respectively. Included in the percentage for international markets is Italy, which represented 9.8% and 10.9% of our net sales for the three and nine months ended September 30, 2010, respectively, and 10.9% and 11.7% of our net sales for the three and nine months ended September 30, 2009, respectively.

We received a CE Mark in Europe for our initial occlusion devices and related delivery systems in 1998. In 2001, we received U.S. regulatory approval to commercialize our AMPLATZER Septal Occluder, which addresses one of the largest treatment areas of the structural heart defect market. We received U.S. regulatory approval to commercialize our AMPLATZER Duct Occluder device in 2003 and our AMPLATZER Muscular VSD Occluder device in 2007.

In addition, we have leveraged our core competencies in braiding nitinol and designing transcatheter delivery systems to develop products for the treatment of certain vascular abnormalities. Our first products in this area, which we launched in the United States in September 2003 and in Europe in January 2004, are vascular plugs for the closure of abnormal blood vessels that develop outside the heart. A second version of our vascular plug was approved and launched in the United States and Europe in August 2007, and a third version was approved in Europe in May 2008. A third and fourth version of our vascular plugs were approved in Europe in May 2008 and July 2009, respectively.

Recent Developments

Table of Contents

the merger. We have agreed not to solicit or initiate discussions with third parties regarding other proposals to acquire the Company and to certain restrictions on its ability to respond to any such proposal, subject to fulfillment of certain fiduciary requirements of our board of directors. The Merger Agreement contains termination rights for both the Company and St. Jude upon various customary circumstances, including if the exchange offer is not completed on or before March 1, 2011, and provides, among other things, that if termination of the Merger Agreement relates to us entering into an acquisition agreement with another party, we will be required to pay St. Jude a termination fee. In such instances, if the alternative transaction is with a party who submitted a proposal received by us prior to 11:59 p.m. Central Time on November 2, 2010 and we notified St. Jude prior to 11:59 p.m. Central Time on November 3, 2010 of our Board’s determination that such proposal was or was reasonably likely to result in a superior proposal to the transaction described in the Merger Agreement, the termination fee will be equal to $21,650,000 (approximately 2% of the equity value for the transaction). In other circumstances when a termination fee is payable under the Merger Agreement, the termination fee payable will be equal to $32,475,000 (approximately 3% of the equity value for the transaction). Under certain circumstances, termination of the Merger Agreement does not preclude St. Jude and Asteroid Subsidiary Corporation from amending and continuing the Offer and promptly disclosing that such Offer is no longer pursuant to the Merger Agreement with AGA.

If our expected merger with St. Jude Medical, Inc. (“St. Jude”) is completed, we expect St. Jude to prepay approximately $207 million of our currently outstanding debt.

A copy of the Merger Agreement was attached as Exhibit 2.1 to our Current Report on Form 8-K filed October 18, 2010 and is incorporated herein by reference.

Recent Acquisitions

Effective January 1, 2009, we began direct distribution in Canada, Portugal, France, and the Netherlands as we purchased on such date the distribution rights, inventory and intangible assets from our distributors in these countries. The aggregate purchase price of these acquisitions totaled $10.8 million, consisting of cash payments of $6.1 million, the discounted value of $1.4 million in additional guaranteed payments and the discounted value of up to $3.3 million in additional contingent payments if certain revenue goals were achieved in fiscal year 2009. On April 1, 2009, we paid our former French distributor $1.4 million in such additional guaranteed payments. During the quarter ended March 31, 2010, we paid all of the contingent payments due in January 2010, which had a fair value of $3.4 million, the contingent payable amounts as of December 31, 2009.

Effective January 1, 2009, we began direct distribution in Italy as a result of our purchase on January 8, 2009 of certain distribution rights, inventory, equipment, intangible assets and goodwill from our former Italian distributor. The aggregate purchase price was $41.0 million, consisting of cash payments of $26.6 million, the discounted value of $9.2 million in additional guaranteed payments and the discounted value of up to $5.2 million in additional contingent payments if certain revenue goals are achieved during the first three years following completion of the acquisition. In addition, on April 1, 2009, we paid our former Italian distributor $2.0 million in other contingent payments for non-revenue based performance. In January 2010, we paid $1.3 million relating to the fiscal year 2009 contingent payment and $3.1 million relating to the January 2010 guaranteed payment.

On January 5, 2009, in order to finance, in part, the acquisition of the assets of our former Italian distributor, AGA Medical issued to an affiliate of Welsh, Carson, Anderson & Stowe IX, L.P., our controlling stockholder, (1) $15.0 million in aggregate principal amount of our 10% senior subordinated notes due 2012 issued in 2009 (the “2009 notes”), and (2) 1,879 shares of Series B preferred stock, which shares of Series B preferred stock were converted to 95,562 shares of our common stock immediately prior to completion of our initial public offering in October 2009. As a result, the discounted issue value of the 2009 notes was $13.1 million.

Effective January 1, 2010, we extended our direct distribution in Canada by purchasing the vascular product distribution rights, inventory, and intangible assets from our former Canadian distributor. The aggregate purchase price was $0.3 million, consisting of cash payments of $0.2 million and the discounted value of up to $0.1 million in additional contingent payment if certain revenue goals are achieved during our 2010 fiscal year.

Use of Constant Currency

As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this Quarterly Report on Form 10-Q, we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Table of Contents

Critical Accounting Policies

A detailed description of our significant accounting policies can be found in our Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 4, 2010.

Results of Operations

Three Months Ended September 30, 2010 Compared to Three Months Ended September 30, 2009

Net sales. Net sales for the quarter ended September 30, 2010 increased 0.6% to $50.5 million from $50.2 million for the same period in 2009. Our family of AMPLATZER Septal Occluder devices represented 51.1% of net product sales for the quarter ended September 30, 2010 and 54.8% of net product sales for the quarter ended September 30, 2009. AMPLATZER PFO Occluder devices represented 13.4% and 14.5% of net sales for the quarters ended September 30, 2010 and 2009, respectively. Vascular plugs represented 10.1% of net product sales for the quarter ended September 30, 2010 and 7.2% of net product sales for the quarter ended September 30, 2009. All other devices represented 13.0% and 11.9% of net product sales for the quarters ended September 30, 2010 and 2009, respectively. Accessories, including delivery systems, represented 12.4% and 11.6% of net product sales for the quarters ended September 30, 2010 and 2009, respectively. Of the total $0.3 million increase in net sales, $0.6 million was derived from U.S. net sales, which represented an increase of 3.4% compared to U.S. net sales for the same period in 2009, offset by a decrease of $0.3 million derived from international net sales, which represented a decrease of 1.1% compared to international net sales for the same period in 2009. The $0.3 million increase in international and U.S. net sales was primarily due to $2.0 million derived from higher volume of units sold, an increase of $0.6 million in freight revenue, restocking fees and adjustments to sales return reserves, offset by a decrease of $1.8 million due to the effects of the appreciation of the U.S. dollar against foreign currencies, and by a decrease of $0.5 million derived from changes in product and geography mix on our international product sales. Sales growth from the prior year quarter was negatively impacted by several items including the significant impact of currency, the delay in receiving FDA clearance for our Amplatzer Vascular Plug 4 and the temporary inability to import and sell products into India. This was resolved in early October and the company has since resumed shipments. The company also experienced a continued delay in the issuance of a significant government tender in a Latin American country. U.S. net sales and international net sales represented 39.5% and 60.5%, respectively, of our total net sales for the quarter ended September 30, 2010, compared to 38.4% and 61.6%, respectively, for the same period in 2009. International direct net sales represented 66.0% and 66.8% of total international net sales for the quarters ended September 30, 2010 and 2009, respectively.

Cost of goods sold. Cost of goods sold for the quarter ended September 30, 2010 increased 2.7% to $6.8 million from $6.6 million for the same period in 2009. The increase was primarily due to higher volume of units sold and product and geography sales mix. Gross margins decreased to 86.6% for the quarter ended September 30, 2010 from 86.8% for the quarter ended September 30, 2009. Excluding the impact of the stronger dollar currency and holding everything else constant, gross margins would have been 86.9% for the quarter ended September 30, 2010.

Selling, general and administrative. Selling, general and administrative expenses for the quarter ended September 30, 2010 decreased 7.5% to $23.5 million from $25.4 million for the same period in 2009. This decrease of $1.9 million primarily resulted from a decrease in legal expenses and the effects of the appreciation of the U.S. dollar against foreign currencies. These decreases were offset by increased costs related to expanding our direct sales force in several European countries and North America associated with the growth of our business. As a percentage of net sales, our selling, general and administrative expenses for the quarter ended September 30, 2010 decreased to 46.6% compared to 50.7% for the same period in 2009.

Research and development. Research and development expenses for the quarter ended September 30, 2010 increased 42.7% to $12.0 million from $8.4 million for the same period in 2009. This increase was primarily attributable to spending increases for new clinical trials and strong patient enrollment for existing trials during the quarter ended September 30, 2010, and partially attributable to increased headcount and outside testing to support both our pre-clinical and development efforts compared with the same period in 2009. As a percentage of net sales, our research and development expenses for the quarter ended September 30, 2010 increased to 23.8% from 16.8% for the same period in 2009.

Amortization of intangible assets. Amortization expenses for the quarter ended September 30, 2010 decreased 2.4% to $5.0 million compared to $5.1 million for the same period in 2009. As a percentage of net sales, amortization of intangible assets for the quarter ended September 30, 2010 decreased to 9.8% from 10.1% for the same period in 2009.

Change in purchase consideration. Change in purchase consideration for the quarter ended September 30, 2010 included a benefit of $0.9 million compared with a benefit of $0.4 million for the same period in 2009. The benefit recorded in the quarter ended September 30, 2010 was derived from the reduction in fair value of the contingent payment obligation resulting from the acquisition of distribution rights from our former distributor in Italy. The benefit recorded in the quarter ended September 30, 2009 was derived from a $0.6 million reduction in fair value of the contingent payment obligations resulting from the acquisition of distribution rights from former distributors in Italy, Canada, and the Netherlands, offset by a $0.2 million increase in fair value of the contingent payment obligations resulting from the acquisitions of distributor rights from former distributors in Portugal and France.

Table of Contents

Interest income. Interest income for the quarter ended September 30, 2010 decreased to $17,000 from $20,000 for the same period in 2009.

Interest expense. Interest expense for the quarter ended September 30, 2010 decreased 30.7% to $2.8 million from $4.0 million for the same period in 2009. The $2.8 million includes a $0.4 million non-cash charge representing a portion of the unamortized debt discount associated with the $15.0 million senior subordinated notes which we prepaid to the extent of $5.0 million during the quarter. The decrease in interest expense reflects the reduction in overall debt, which was directly attributable to the use of the proceeds from the initial public offering in 2009 and lower average interest rates for the quarter ended September 30, 2010. This was partially offset due to the on-going accretion of the discount associated with the Medtronic litigation settlement charge.

Other income (expense), net. Other income (expense), net for the quarter ended September 30, 2010 was an expense of $0.5 million, as compared to income of $0.3 million for the same period in 2009, mainly as a result of foreign exchange losses in the quarter ended September 30, 2010 compared to foreign exchange gains in the quarter ended September 30, 2009.

Income tax benefit. Income tax benefit for the quarter ended September 30, 2010 was $0.6 million as compared to a $0.9 million benefit for the same period in 2009, primarily due to foreign and federal tax return true-ups and the release of valuation allowances against foreign subsidiaries’ net operating losses and other tax assets.

Net income. Net income for the quarter ended September 30, 2010 was $1.5 million as compared to net income of $2.2 million for the same period in 2009. The decrease in net income was primarily attributable to higher research and development expense during the quarter ended September 30, 2010, as discussed above.

Nine Months Ended September 30, 2010 Compared to Nine Months Ended September 30, 2009

Net sales. Net sales for the nine months ended September 30, 2010 increased 7.6% to $155.5 million from $144.5 million for the same period in 2009. Our family of AMPLATZER Septal Occluder devices represented 50.9% of net product sales for the nine months ended September 30, 2010 and 55.1% of net product sales for the nine months ended September 30, 2009. AMPLATZER PFO Occluder devices represented 13.9% and 15.0% of net sales for the nine months ended September 30, 2010 and 2009, respectively. Vascular plugs represented 10.0% of net product sales for the nine months ended September 30, 2010 and 7.0% of net product sales for the nine months ended September 30, 2009. All other devices represented 13.2% and 11.1% of net product sales for the nine months ended September 30, 2010 and 2009, respectively. Accessories, including delivery systems, represented 12.0% and 11.8% of net product sales for the nine months ended September 30, 2010 and 2009, respectively. Of the total $11.0 million increase in net sales, $8.5 million was derived from international net sales, which represented an increase of 9.6% compared to international net sales for the same period in 2009, and $2.5 million was derived from increased U.S. net sales, which represented an increase of 4.4% compared to U.S. net sales for the same period in 2009. The $11.0 million increase in international and U.S. net sales was primarily due to $14.6 million derived from higher volume of units sold and a $0.9 million increase in freight revenue, restocking fees and adjustments to sales return reserves. These increases were offset by a decrease of $3.1 million relating to changes in product and geography mix and a $1.4 million decrease due to changes in currency compared to the same period in 2009. Sales growth from the year ago period was negatively impacted by several items including the significant impact of currency, the delay in receiving FDA clearance for our Amplatzer Vascular Plug 4 and the temporary inability to import and sell products into India. This was resolved in early October and the company has since resumed shipments. The company also experienced a continued delay in the issuance of a significant government tender in a Latin American country. U.S. net sales and international net sales represented 37.6% and 62.4%, respectively, of our total net sales for the nine months ended September 30, 2010, compared to 38.8% and 61.2%, respectively, for the same period in 2009. International direct net sales represented 67.5% and 68.2% of total international net sales for the nine months ended September 30, 2010 and 2009, respectively.

Cost of goods sold. Cost of goods sold for the nine months ended September 30, 2010 decreased 7.8% to $21.8 million from $23.6 million for the same period in 2009. This decrease in cost of goods sold was mainly attributable to $3.7 million of prior year expenses associated with the repurchase of inventory from former distributors whose distribution rights were acquired in January 2009, partially offset by higher volume of units sold and product and geography sales mix. Gross margins increased to 86.0% for the nine months ended September 30, 2010 from 83.7% for the nine months ended September 30, 2009. Excluding the $3.7 million of repurchased inventory charges in 2009, gross margins for the nine months ended September 30, 2009 were 86.3%. Gross margin for the nine months ended September 30, 2010 was 86.4% on a constant currency basis.

Selling, general and administrative. Selling, general and administrative expenses for the nine months ended September 30, 2010 increased 2.0% to $73.4 million from $71.9 million for the same period in 2009. This increase of $1.5 million was due to an increase in costs related primarily to expanding our direct sales force in several European countries and North America associated with the expansion of our business, and offset by a decrease in general and administrative expenses, primarily due to lower legal fees and the effects of the appreciation of the U.S. dollar against foreign currencies. As a percentage of net sales, our selling, general and

Table of Contents

administrative expenses for the nine months ended September 30, 2010 decreased to 47.2% compared to 49.7% for the same period in 2009.

Research and development. Research and development expenses for the nine months ended September 30, 2010 increased 35.1% to $33.6 million from $24.9 million for the same period in 2009. This increase was primarily attributable to spending increases for new clinical trials and higher patient enrollment for existing trials during the nine months ended September 30, 2010, and partially attributable to increased headcount to support both our pre-clinical and development efforts compared with the same period in 2009. As a percentage of net sales, our research and development expenses for the nine months ended September 30, 2010 increased to 21.6% from 17.2% for the same period in 2009.

Litigation settlement. The litigation settlement expense of $31.9 million for the nine months ended September 30, 2010 was attributable to the settlement reached with Medtronic related to the Jervis patent lawsuit, as described in more detail in Note 9 to our unaudited consolidated financial statements included in Part I, Item 1 of this Report, and represents the discounted value of the $35.0 million settlement to be paid over four years.

Amortization of intangible assets. Amortization expenses for the nine months ended September 30, 2010 decreased 0.3% to $14.9 million compared to $15.0 million for the same period in 2009. As a percentage of net sales, amortization of intangible assets for the nine months ended September 30, 2010 decreased to 9.6% from 10.4% for the same period in 2009.

Change in purchase consideration. Change in purchase consideration for the nine months ended September 30, 2010 included a benefit of $1.1 million compared with a benefit of $1.1 million for the same period in 2009. The benefit recorded in the nine months ended September 30, 2010 is derived from the reduction in fair value of the contingent payment obligation resulting from the acquisition of distribution rights from our former distributor in Italy. The benefit recorded in the nine months ended September 30, 2009 is derived from a $1.3 million reduction in fair value of the contingent payment obligations resulting from the acquisition of distribution rights from former distributors in Italy and Canada, offset by a $0.2 million increase in fair value of the contingent payment obligations resulting from the acquisitions of distributor rights from former distributors in Portugal and France.

Investment loss. The $2.4 million loss in 2009 reflected a write-off of our investment in Ample Medical, Inc., a privately-held, early stage company focused on pre-clinical studies relating to the development of minimally invasive devices to treat structural heart defects. For additional information, see Note 14 to our unaudited consolidated financial statements included in Part I, Item 1 of this Report.

Interest income. Interest income for the nine months ended September 30, 2010 decreased to $77,000 from $80,000 for the same period in 2009.

Interest expense. Interest expense for the nine months ended September 30, 2010 decreased 40.6% to $7.2 million from $12.1 million for the same period in 2009. The $7.2 million includes a $0.4 million non-cash charge representing a portion of the unamortized debt discount associated with the $15.0 million senior subordinated notes which we prepaid to the extent of $5.0 million during the period. The decrease in interest expense reflects the reduction in overall debt, which was directly attributable to the use of the proceeds from the initial public offering in 2009 and lower average interest rates for the nine months ended September 30, 2010. This was partially offset by the accretion of the discount associated with the Medtronic litigation settlement charge taken in the first quarter of 2010.

Other income (expense), net. Other income (expense), net for the nine months ended September 30, 2010 was an expense of $0.7 million, as compared to income of $1.6 million for the same period in 2009, mainly as a result of foreign exchange losses for the nine months ended September 30, 2010 compared to foreign exchange gains for the nine months ended September 30, 2009.

Income tax expense (benefit). Income tax benefit for the nine months ended September 30, 2010 was $10.7 million as compared to a $0.6 million benefit for the same period in 2009, due to lower pre-tax income, primarily resulting from the Medtronic litigation settlement.

Net loss. Net loss for the nine months ended September 30, 2010 was $16.1 million as compared to net loss of $2.0 million for the same period in 2009. The increase to the net loss was primarily attributable to the litigation settlement expense incurred in the first quarter of 2010 and higher research and development expense during the nine-months ended September 30, 2010, as discussed in more detail above.

Table of Contents

Liquidity and Capital Resources

Our principal sources of liquidity are existing cash, internally generated cash flow and borrowings under our senior secured credit facility. We believe that these sources will provide sufficient liquidity for us to meet our liquidity requirements for the next 12 months. Our principal liquidity requirements are to service our debt and to meet our working capital, research and development, including clinical trials, and capital expenditure needs. We may, however, require additional liquidity as we continue to execute our business strategy. We anticipate that to the extent that we require additional liquidity, it will be funded through the incurrence of indebtedness, equity financings or a combination of these potential sources of liquidity. We cannot assure you that we will be able to obtain this additional liquidity on reasonable terms, or at all. Additionally, our liquidity and our ability to fund our capital requirements is also dependent on our future financial performance, which is subject to general economic, financial and other factors that are beyond our control.

Restricted cash balances that are pledged as collateral for letters of credit affect our liquidity. The majority of letters of credit are issued in currencies other than U.S. dollar. Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our liquidity and require increases to our restricted cash balances. As of September 30, 2010, we had restricted cash of $8.3 million compared to $3.3 million as of December 31, 2009, an increase of $5.0 million. Restricted cash is expected to become available to us upon satisfaction of the obligations pursuant to which the letters of credit were issued.

Cash Flows

Cash Flows Provided By Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2010 increased to $12.1 million from $6.8 million of net cash provided in operating activities for the nine months ended September 30, 2009. This increase was primarily attributable to the following changes in cash flows for the nine months ended September 30, 2010 compared to the same period in 2009: a $24.4 million increase to the provision related to Medtronic litigation, a net $2.2 million increase in non-cash items, including depreciation, amortization, debt discount accretion, write-off of unamortized discount on long-term debt, deferred financing cost amortization, and stock-based compensation expense, and a net increase of $5.3 million related to changes in working capital balances and a $2.4 million decrease in losses on our equity investment due to our impairment and write-off of this investment during March 2009, which were partially offset by a $14.1 million increase in net loss and a $10.1 million decrease in deferred taxes.

Cash Flows Used In Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2010 decreased to $12.6 million from $45.0 million for the same period in 2009. This decrease was primarily attributable to the following changes in cash flows for the nine months ended September 30, 2010 compared to the same period in 2009: a $28.6 million decrease related to acquisitions of distribution rights from former distributors and a $5.1 million decrease in purchases of property and equipment, which was partially offset by a $4.1 million increase in restricted cash and a $2.8 million increase in proceeds from litigation settlement related to the Occlutech litigation.

Cash Flows Provided by (used in) Financing Activities

Net cash provided by (used in) financing activities for the nine months ended September 30, 2010 was a use of cash of $4.2 million as compared to $28.2 million provided by financing activities for the same period in 2009. This decrease was primarily attributable to the following changes in cash flows for the nine months ended September 30, 2010 compared to the same period in 2009: $10.0 million total increase in payments to long-term debt and payments to our revolving credit facility, a $10.0 million decrease in amounts drawn under our revolving credit facility, and a $15.0 million decrease from the issuance of notes, which factors were partially offset by a $0.3 million increase in cash from the issuance of common stock under employee stock purchase plan and $1.0 million increase in cash from proceeds from exercise of stock options, and a $1.0 million decrease in cash used for payments of deferred financing fees.

Cash Position and Indebtedness

Our total gross indebtedness exclusive of discounts was $222.3 million at December 31, 2009 and $241.3 million at September 30, 2010.

As of September 30, 2010, our senior secured credit facility consisted of a $215.0 million seven-year Tranche B term loan facility and a revolving credit facility. The Tranche B term loan facility matures on April 28, 2013. On April 14, 2010, we borrowed

Table of Contents

$5.0 million under the revolving credit facility to provide sufficient funds to pay Medtronic $7.5 million due under the settlement and license agreement entered into on March 26, 2010. On May 13, 2010, we repaid $5.0 million under the revolving credit facility.

On August 3, 2010, our revolving credit facility was increased from $25.0 million to $40.0 million, with a new maturity date of January 28, 2013. The maturity date will be January 28, 2012 if the senior subordinated notes due 2012 have not been retired in full by January 28, 2012. No change was made to the guarantors, collateral, the representations and warranties or the covenants. We incurred deferred financing fees of approximately $0.7 million that will be recorded to interest expense over the term of the revolving credit facility.

As of September 30, 2010, we did not have outstanding borrowings under our revolving credit facility and had $197.0 million outstanding under our Tranche B term loan facility.

Our senior secured credit facility contains customary covenants, including restrictions on our ability to incur indebtedness, grant liens, pay dividends, sell our assets, effect a change of control, use funds for capital expenditures, make investments, make optional payments or modify debt instruments, or enter into sale and leaseback transactions. Our senior secured credit facility also requires us to maintain compliance with specified financial covenants. As of September 30, 2010, we were in compliance with all of our financial covenants specified in our senior secured credit facility. Our senior secured credit facility also contains customary events of default. Upon the occurrence of an event of default, lenders thereunder may cease to make loans and declare amounts outstanding to be immediately due and payable. The indebtedness under our senior secured credit facility is secured by a perfected first priority security interest in all of our tangible and intangible assets (including, without limitation, intellectual property, owned real property and all of our capital stock and each direct and indirect subsidiaries, provided that no assets of any foreign subsidiary is included as collateral and no more than 65% of the voting stock of any first-tier foreign subsidiary is required to be pledged).

The following table sets forth the amounts outstanding under our Tranche B term loan facility and our revolving credit facility, the effective interest rates on such outstanding amounts and amounts available for additional borrowing thereunder as of September 30, 2010. As discussed under the subsection of this Part I, Item 2 entitled “Recent Developments,” if the transactions contemplated by the Merger Agreement are completed, St. Jude expects to prepay a portion of our debt.

Senior Secured Credit Facility	Effective Interest Rate		Amount Outstanding		Amount Available for Additional Borrowing
			(dollars in millions)
Revolving Credit Facility	4.76	%	$	—	$	40.0
Tranche B Term Loan Facility	2.50	%	197.0		—
Total			$	197.0	$	40.0

In addition to our Tranche B term loan facility and our revolving credit facility, as of September 30, 2010, we had $10.0 million outstanding aggregate principal amount of 2009 notes. The effective interest rate of the 2009 notes at September 30, 2010 was 19.1%, compounded semiannually. In September 2010 the Company made a prepayment of $5.0 million, reducing the principal balance from $15.0 million to $10.0 million. In conjunction with the voluntary prepayment the Company recorded a non-cash charge of $0.4 million representing the related portion of the unamortized debt discount. As part of the securities purchase agreement entered into in connection with the issuance of the 2009 notes, AGA Medical issued 1,879 shares of Series B preferred stock valued at $1.9 million to the purchaser of the 2009 notes, which shares of Series B preferred stock were converted to 95,562 shares of our common stock immediately prior to completion of our initial public offering. As a result, the discounted issue value of the 2009 notes was $13.1 million. As of September 30, 2010, the accreted value of the outstanding 2009 notes on our balance sheet was $9.3 million. The $1.9 million of discount from the face value is being accreted on our balance sheet to the 2009 notes repayment amount utilizing the effective interest rate. The original issue discount has been recognized as interest expense of $0.5 million and $0.7 million for the three and nine months ended September 30, 2010, respectively, and $0.1 million and $0.4 million for the three and nine months ended September 30, 2009, respectively. The interest expense for the three and nine months ended September 30, 2010 includes $0.4 million write-off of the unamortized debt discount recorded in conjunction with $5.0 million prepayment made in September 2010. Total original issue discount recorded to interest expense from date of issuances of notes is $1.2 million. Interest on the 2009 notes is payable on a semiannual basis in arrears on January 1 and July 1 of each year.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Table of Contents

Seasonality

While our results of operations are not materially affected by seasonality, our net sales are affected by holiday and vacation periods, especially in the first and third quarters in Europe.

PART I — FINANCIAL INFORMATION

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Foreign Exchange Risk Management

Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our financial results. Approximately $89.1 million, or 44.8% and $65.8 million, or 42.3%, of our net sales were denominated in foreign currencies for the year ended December 31, 2009 and the nine months ended September 30, 2010, respectively. Selling, marketing and general costs related to these foreign currency sales are largely denominated in the same respective currency, thereby partially offsetting our foreign exchange risk exposure. For sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases and if we price our products in the foreign currency, we will receive less in U.S. dollars than we did before the rate increase went into effect. If we price our products in U.S. dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our price not being competitive in a market where business is transacted in the local currency.

In the first quarter of 2009, we initiated a foreign currency hedging program. The objectives of the program are to reduce earnings volatility due to movements in foreign currency markets, limit loss in foreign currency-denominated cash flows, and preserve the operating margins of our foreign subsidiaries. We generally use foreign currency forward contracts to hedge transactions related to known inter-company sales and inter-company debt. We also may hedge firm commitments. These contracts generally relate to our European operations and are denominated primarily in Euros and sterling. All of our foreign exchange contracts are recognized on the balance sheet at their fair value. We do not enter into foreign exchange contracts for speculative purposes. We recorded losses from foreign currency forward contracts of $2.3 million and $0.5 million for the three and nine months ended September 30, 2010, respectively and we recorded gains from foreign currency forward contracts of $0.3 million and $0.2 million for the three and nine months ended September 30, 2009, respectively. These are reflected on the consolidated statement of operations in the other income (expense), net line. Amounts on our balance sheet at September 30, 2010 and December 31, 2009 are immaterial.

Interest Rate Risk

We are exposed to interest rate risk in connection with our Tranche B term loan facility and any borrowings under our revolving credit facility, which bear interest at floating rates based on Eurodollar or the greater of prime rate or the federal funds rate plus an applicable borrowing margin. For variable rate debt, interest rate changes generally do not affect the fair value of the debt instrument, but do impact future earnings and cash flows, assuming other factors are held constant.

We entered into an amended and restated senior secured credit agreement in connection with our April 2006 recapitalization and repaid our prior senior term loan. The transaction resulted in a $215.0 million Tranche B term loan facility and a revolving credit facility of $25.0 million.

As of September 30, 2010, we had outstanding borrowings of $197.0 million under the Tranche B term loan facility and no amounts outstanding under our revolving credit facility as of September 30, 2010 and December 31, 2009.

ITEM 4. Controls and Procedures

Disclosure Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) are effective, in all material respects, to ensure that information we are required to disclose in reports that we file or submit under the

Table of Contents

Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There were no changes in our internal controls over financial reporting during the third quarter of fiscal year 2010 that may have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

Management believes that the claims involved in these complaints are without merit and does not expect the litigations to have a material adverse effect on our business, financial condition, or results of operations. We will, however, incur costs and diversion of management resources in defending the claims. Moreover, because litigation is inherently uncertain, we cannot guarantee that the outcome of these litigations will be favorable to us, that the litigation will not delay or prevent completion of the transactions contemplated by the Merger Agreement, or that material damages will not be awarded against us.

In addition, other than the Occlutech judgment, Medtronic litigation settlement and the Gore litigation described in Note 9 to our unaudited consolidated financial statements included in Part I, Item 1 of this Report: Commitments and Contingencies (Litigation), there have been no material changes in the information provided under the heading “Legal Proceedings” in our Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 4, 2010.

Item 1A. Risk Factors.

If our merger transaction with St. Jude Medical, Inc. is not completed or is delayed, our share price, business and results of operations may materially suffer.

Table of Contents

It is possible the merger transaction with St. Jude Medical, Inc. might not be completed or could be delayed for a number of reasons. If the consummation of the merger is delayed or otherwise not consummated within the contemplated time periods or not at all, we could suffer a number of consequences that may adversely affect our business, results of operations and share price materially, including:

· a loss of revenue and market position that we may not be able to regain if the proposed transactions are not consummated;

· damage to our relationships with our customers, suppliers, and other business partners;

· a potential obligation to pay a $32.5 million (or, in certain circumstances, $21.7 million) termination fee depending on the reasons for terminating the merger transaction;

· significant costs related to the proposed transaction, including substantial legal, accounting and investment banking expenses;

· key employees may be lost during the pendency of the merger and our relationships with employees may be damaged; and

· business and organizational opportunities may be lost due to covenants in the merger agreement that restrict certain actions by us prior to completion of the merger

A lawsuit has been filed and additional lawsuits may be filed against us and the members of our board of directors arising out of the merger transaction with St. Jude Medical, Inc.

As a result of entering into the Merger Agreement and engaging in the transactions contemplated thereby, we may become subject to additional lawsuits on behalf of stockholders alleging that our directors breached their fiduciary duties, challenging the fairness of the consideration to be received by stockholders, or making other claims regarding the fairness of the Merger Agreement and the transactions contemplated thereby. Such lawsuits may seek to prevent completion of the merger transaction or to rescind the transaction after it has occurred. We may also be subject to litigation related to any failure to complete the transaction or subject to enforcement proceedings to perform our obligations under the Merger Agreement.

The outcome of all litigation is uncertain and we may not be successful in defending against such claims. Moreover, regardless of the outcome of any such lawsuit, it could delay or prevent completion of the transactions contemplated by the Merger Agreement, divert the attention of our management and employees from day-to-day business operations, and otherwise adversely affect our business, financial condition, and results of operations.

Healthcare policy changes, including new legislation to reform the U.S. healthcare system, may have a material adverse effect on us.

Table of Contents

On March 23, 2010, the Patient Protection and Affordable Care Act was enacted and was subsequently amended by the enactment on March 30, 2010 of the Health Care and Education Reconciliation Act. Together, these laws are commonly referred to as “Health Care Reform.” The Health Care Reform legislation may not be implemented in its present form and any implementation will likely take several years. The full timing and financial impact of Health Care Reform on our business operations and financial statements is uncertain. However, Health Care Reform as enacted includes the following provisions: (i) a medical device tax of 2.3%; (ii) creation of an independent medical advisory board to reduce Medicare spending and other national health expenditures by targeted percentages over several years; (iii) creation of a patient-centered outcomes research institute to conduct comparative effectiveness of medical treatments which may make findings that may be used to make public health care insurance coverage decisions; and (iv) creation of other programs which may reduce public and private health care expenditures. Any of these provisions or other provisions of the Health Care Reform legislation could increase our taxes, limit the prices we are able to charge for our products or the amounts of reimbursement available for our products, and could limit the acceptance and availability of our products. The full implementation of some or all of these provisions could have a material adverse effect on our financial position and results of operations.

There have been no other material changes in the information provided under the heading “Risk Factors” in our Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 4, 2010.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities.

None.

Use of Proceeds.

The effective date of our registration statement filed on Form S-1 under the Securities Act of 1933 (File No. 333-151822) relating to our initial public offering of shares of common stock, $0.01 par value was October 20, 2009. A total of 15,812,500 shares of our common stock were registered and 13,750,000 were sold, including 6,509,000 shares of common stock sold by us and 7,241,000 shares of common stock sold by the selling stockholders. The option we granted to the underwriters to purchase up to 2,062,500 additional shares of our common stock expired without being exercised. Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Leerink Swann LLC and Wells Fargo Securities, LLC acted as joint book-running managers of the offering.

The aggregate offering price of securities registered was $229,281,250 and the aggregate amount sold was $199,375,000. The aggregate underwriting discount was $12,959,375, none of which was paid to our affiliates. We incurred approximately $5.0 million of other expenses in connection with the offering. Net proceeds we received from this offering totaled approximately $82.2 million. We used $25.0 million of the net proceeds from our initial public offering to fully repay principal and accrued and unpaid interest under our revolving credit facility. We used $50.0 million of the net proceeds from our initial public offering to prepay the principal amount of our 10% senior subordinated notes due 2012 that were issued in 2005, or the 2005 notes. In addition, we used approximately $5.0 million of the net proceeds from our initial public offering to pay accrued and unpaid interest on the 2005 notes and the 10% senior subordinated notes due 2012 that were issued in 2009. The remaining proceeds from our IPO are being used for working capital and general corporate purposes.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. (Removed and Reserved).

Item 5. Other Information.

On August 23, 2010, Dr. Kurt Amplatz extended his research and development contract that was set to expire in December 2010 for an additional five-year term. Dr. Amplatz’s research and development contract is now set to expire in December 2015. A copy of the amendment to Dr. Amplatz’s research and development contract is attached as Exhibit 10.1 and is incorporated herein by reference.

Item 6. Exhibits.

See Exhibit Index.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AGA MEDICAL HOLDINGS, INC. (Registrant)

Date: November 9, 2010		By:	/s/ John R. Barr
		Name: John R. Barr
		Title: President and Chief Executive Officer
		(Principal Executive Officer)

Date: November 9, 2010		By:	/s/ Brigid A. Makes
		Name: Brigid A. Makes
		Title: Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibit Number		Description of Exhibit
2.1		Agreement and Plan of Merger and Reorganization — incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on October 18, 2010.
3.1		Form of Amended and Restated Certificate of Incorporation of AGA Medical Holdings, Inc.—incorporated by reference to Exhibit 3.1 to our Registration Statement on Form S-1/A filed on October 20, 2009.
3.2		Form of Amended and Restated Bylaws of AGA Medical Holdings, Inc.—incorporated by reference to Exhibit 3.2 to our Registration Statement on Form S-1/A filed on October 1, 2009.
10.1*		Amendment, dated August 23, 2010 to Research Agreement with Dr. Kurt Amplatz dated December 23, 2005
31.1*		Rule 13a-14(a) Certification of Principal Executive Officer
31.2*		Rule 13a-14(a) Certification of Principal Financial Officer
32*		Section 1350 Certification of Principal Executive Officer and Principal Financial Officer
99.1		Complaint filed on October 29, 2010 in Hennepin County District Court, Fourth Judicial District, State of Minnesota (Rubin v. AGA Medical Holdings, Inc., et al.), incorporated by reference to Exhibit (a)(5)(D) to Amendment No. 1 to the Tender OFFER Statement on Schedule TO filed with the Securities and Exchange Commission by St. Jude Medical, Inc. on October 29, 2010.
99.2		Complaint filed on October 28, 2010 in the Delaware Court of Chancery (Walling v. AGA Medical Holdings, Inc., et al.), incorporated by reference to Exhibit (a)(5)(E) to Amendment No.1 to the Tender OFFER Statement on Schedule TO filed with the Securities and Exchange Commission by St. Jude Medical, Inc. on October 29, 2010

*Filed herewith

AGA Medical Holdings, Inc. 10-Q